Surveillance for hepatocellular carcinoma.

Area of Science:

• Hepatology
• Oncology
• Diagnostic Imaging

Background:

• Hepatocellular carcinoma (HCC) surveillance is vital for early detection, primarily through semiannual abdominal ultrasound (US) in at-risk patients.
• Tumor growth rates in cirrhotic patients average six months for volume doubling, supporting a six-month screening interval.
• Metabolic diseases like diabetes and obesity, linked to insulin resistance and non-alcoholic steatohepatitis (NASH), are increasingly recognized as HCC risk factors.

Purpose of the Study:

• To review the current strategies and challenges in early hepatocellular carcinoma (HCC) detection and surveillance.
• To highlight the diagnostic capabilities and limitations of imaging modalities like ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) for HCC.
• To discuss the evidence supporting screening benefits and the barriers hindering its effectiveness.

Main Methods:

• Review of existing literature on HCC surveillance, diagnostic imaging, and risk factors.
• Analysis of the role of abdominal ultrasound (US), CT, and MRI in detecting HCC, particularly nodules <1 cm.
• Discussion of clinical, histological, and genetic factors influencing screening effectiveness and patient stratification.

Main Results:

• Early HCC diagnosis is achievable through semiannual surveillance, significantly improving treatment response compared to incidentally detected tumors.
• Imaging modalities like CT and MRI are effective for diagnosing HCC >1 cm, but smaller nodules (<1 cm) require enhanced follow-up with US.
• Despite evidence supporting screening benefits, barriers such as limited knowledge, financial incentives, and access to care impede its effectiveness.

Conclusions:

• Semiannual screening with abdominal ultrasound (US) remains the primary strategy for early hepatocellular carcinoma (HCC) detection in at-risk populations.
• While advanced imaging aids diagnosis, challenges persist in detecting small HCC nodules, necessitating careful follow-up.
• Overcoming barriers to screening and refining patient selection criteria are crucial for maximizing the benefits of HCC surveillance.